OpenAI's IPO Postponed to 2027, Microsoft Xbox Prices to Rise
Money

OpenAI's IPO Postponed to 2027, Microsoft Xbox Prices to Rise

authorBy Chika Uwazie
DateJun 27, 2026
Read Time3 min

OpenAI, financially supported by Microsoft, is reportedly postponing its anticipated public offering until the year 2027. This decision follows earlier intentions to launch an IPO as early as the third or fourth quarter of 2026, with CEO Sam Altman reportedly pushing for a staggering $1 trillion valuation. Simultaneously, Microsoft has unveiled plans to increase the price of its Xbox consoles globally, effective August 1, 2026, citing a significant surge in the cost of console components. Furthermore, the company has forged a new alliance with PitchBook, integrating private capital market data into its Microsoft 365 Copilot suite, enhancing financial analysis and research capabilities for its users.

Microsoft-Backed OpenAI Delays IPO, Xbox Console Prices Set to Increase, and New Partnership with PitchBook Announced

On June 26, 2026, reports surfaced from the New York Times, citing sources close to the matter, indicating that OpenAI, a leading artificial intelligence research and deployment company with significant backing from Microsoft Corporation (NASDAQ:MSFT), is now leaning towards delaying its initial public offering (IPO) until 2027. This postponement comes despite previous discussions to take the company public as early as the latter half of 2026, with an ambitious target of achieving a $1 trillion valuation. Sam Altman, OpenAI's CEO, had reportedly been actively engaging with financial advisors to prepare for this monumental public debut.

Concurrently, on the very same day, Microsoft made a significant announcement regarding its Xbox gaming division. Effective August 1, 2026, the global prices for Xbox consoles are slated to increase. The 512 GB models will see a price hike of $100, while the 1 TB models will become $150 more expensive. Moreover, Microsoft plans to discontinue its 2 TB Xbox model. The company attributed these price adjustments to a substantial increase in console storage and memory costs, which have reportedly more than doubled in recent times, with further increases anticipated by the autumn of 2027. Microsoft emphasized that the current global components crisis has particularly impacted the console market, where products are often sold below their manufacturing cost.

Adding to its strategic moves, on June 25, PitchBook unveiled a new federated Copilot connector with Microsoft. This innovative collaboration aims to integrate private capital market data directly into Microsoft 365 Copilot, including its applications like Copilot in Excel, Copilot Chat, and Researcher. This integration will empower licensed users of both Microsoft 365 Copilot and PitchBook to leverage the PitchBook Copilot agent within Microsoft 365. This will facilitate easier access to insights, aid in building financial models, summarize research, and create comprehensive presentations. Specifically, within Copilot in Excel, finance professionals can utilize this connector to develop target lists, streamline due diligence workflows, and screen investment opportunities using PitchBook's extensive company profiles, deal histories, fund data, and analyst research.

The current market landscape for technology and AI companies is dynamic and complex. OpenAI's decision to delay its IPO, despite its ambitious valuation goals, suggests a strategic recalibration in response to market conditions or internal development timelines. This move highlights the cautious approach many high-growth companies are taking when considering public listings. On the other hand, Microsoft's decision to increase Xbox prices, directly attributing it to escalating component costs and supply chain challenges, underscores the broader economic pressures faced by hardware manufacturers. This reflects a trend of companies adjusting their pricing strategies to maintain profitability amidst inflationary pressures and supply constraints. The partnership with PitchBook, however, showcases Microsoft's continued commitment to expanding the capabilities of its AI-powered tools and solidifying its position in the enterprise software market, particularly in the financial sector. These events collectively paint a picture of a tech giant navigating both strategic growth opportunities and market-driven challenges, constantly adapting its business models to remain competitive and innovative.

More Articles
Money
Apple Shifts Mac Chip Strategy Towards AI with M7 Focus
Apple is reportedly reorienting its Mac chip development to prioritize AI, with plans for an M7 chip in 2027 that will feature significant AI-focused enhancements. This strategic move aims to meet the escalating demand for on-device AI capabilities and more advanced graphics software. Concurrently, Apple has implemented rare mid-cycle price adjustments for various Mac and iPad models, citing increased memory and storage costs driven by AI data center expansion. These price hikes, ranging from 17% to 25%, are intended to safeguard profit margins, although they could potentially impact consumer demand.
By Bola SokunbiJun 27, 2026
Money
Novo Nordisk: A Leading Low Volatility Stock Under $50?
Novo Nordisk A/S (NVO) has emerged as a top contender among low-volatility stocks under $50, especially following the UK's approval of its oral weight-loss medication, Wegovy®. This groundbreaking pill offers a non-injectable alternative for adults managing obesity or overweight conditions, marking a significant advancement in the treatment landscape. The company's focus on diabetes and obesity care, including GLP-1 products, positions it as a key player in the global healthcare market.
By Vicki RobinJun 27, 2026
Money
AbbVie's Strategic Acquisition of Apogee Therapeutics to Bolster Immunology Portfolio
AbbVie Inc. recently announced its plan to acquire Apogee Therapeutics, a move set to significantly enhance its immunology and inflammatory disease pipeline. This acquisition, valued at approximately $10.9 billion, will integrate Apogee's clinical-stage candidates for conditions like asthma and atopic dermatitis into AbbVie's existing portfolio, strengthening its presence in the respiratory therapeutic area. The boards of both companies have approved the transaction, with an anticipated closure in fiscal Q3 2026, pending shareholder and regulatory approvals.
By Natalie PaceJun 27, 2026
Money
Eli Lilly and BioArctic Forge Alliance for Neurodegenerative Treatment
Eli Lilly and Company and BioArctic AB have entered into a research and collaboration agreement to develop a novel treatment for neurodegeneration. This partnership combines BioArctic's BrainTransporter technology with an undisclosed Lilly drug candidate. BioArctic stands to receive a $30 million upfront payment and potential milestone payments up to $770 million, plus royalties on future global sales. Eli Lilly will manage global development and commercialization. The collaboration aims to address critical needs in neuroscience with innovative pharmaceutical solutions.
By Chika UwazieJun 27, 2026
Money
Starbucks' Ambitious Expansion: A Strategy to Redefine the Coffee Experience
Starbucks CEO Brian Niccol is steering the company towards an ambitious expansion plan, aiming to add 10,000 new U.S. locations. This strategy involves smaller store formats and a renewed focus on community and personalized customer experiences, moving beyond its pandemic-era takeout model. Niccol emphasizes creating a 'third place' for connection and customization, believing this approach will drive long-term growth and differentiate Starbucks from competitors like Dutch Bros and 7 Brew.
By Bola SokunbiJun 27, 2026